Literature DB >> 17089867

Craniopharyngioma in childhood.

Joshua A May1, Mark D Krieger, Ira Bowen, Mitchell E Geffner.   

Abstract

In summary, much progress has been made in our understanding of childhood craniopharyngiomas. These histologically benign but "geographically malignant" tumors are challenging to treat and require experienced clinicians from multiple disciplines including neurosurgery, radiology, hematology/oncology, ophthalmology, endocrinology, and general pediatrics to address the multiple issues that arise with diagnosis, treatment, and long-term follow-up of affected children. The study and close observation of patients who have craniopharyngiomas may also be beneficial for our general understanding of pathophysiologic processes such as the observed "growth without growth hormone" phenomenon or the well-described and studied hypothalamic obesity phenotypes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089867     DOI: 10.1016/j.yapd.2006.04.013

Source DB:  PubMed          Journal:  Adv Pediatr        ISSN: 0065-3101


  4 in total

1.  Cognitive and social functioning in children and adolescents after the removal of craniopharyngioma.

Authors:  Agnieszka Ondruch; Agnieszka Maryniak; Tomasz Kropiwnicki; Marcin Roszkowski; Paweł Daszkiewicz
Journal:  Childs Nerv Syst       Date:  2010-10-08       Impact factor: 1.475

2.  Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas.

Authors:  D F Ierardi; M J S Fernandes; I R Silva; J Thomazini-Gouveia; N S Silva; P Dastoli; S R C Toledo; S Cavalheiro
Journal:  Childs Nerv Syst       Date:  2007-06-26       Impact factor: 1.475

Review 3.  Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans.

Authors:  Michelle Lee; Judith Korner
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 4.  Obesity and craniopharyngioma.

Authors:  Lorenzo Iughetti; Patrizia Bruzzi
Journal:  Ital J Pediatr       Date:  2011-08-16       Impact factor: 2.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.